董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jon Congleton | 男 | President, Chief Executive Officer, and Director | 62 | 154.70万美元 | 未持股 | 2026-03-12 |
| Derek DiRocco | 男 | Independent Director | 46 | 未披露 | 未持股 | 2026-03-12 |
| Brian Taylor Slingsby | 男 | Independent Director | 49 | 未披露 | 未持股 | 2026-03-12 |
| Daphne Karydas | -- | Independent Director | -- | 未披露 | 未持股 | 2026-03-12 |
| Glenn Sblendorio | -- | Chairman and Independent Director | -- | 未披露 | 未持股 | 2026-03-12 |
| Alexander M. Gold | -- | Independent Director | -- | 未披露 | 未持股 | 2026-03-12 |
| Srinivas Akkaraju | 男 | Independent Director | 57 | 未披露 | 未持股 | 2026-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jon Congleton | 男 | President, Chief Executive Officer, and Director | 62 | 154.70万美元 | 未持股 | 2026-03-12 |
| David Rodman | 男 | Chief Medical Officer | 70 | 91.57万美元 | 未持股 | 2026-03-12 |
| Adam Levy | 男 | Chief Financial Officer and Secretary | 47 | 82.57万美元 | 未持股 | 2026-03-12 |
| Eric Warren | 男 | Chief Commercial Officer | 53 | 未披露 | 未持股 | 2026-03-12 |
董事简历
中英对照 | 中文 | 英文- Jon Congleton
-
Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
Jon Congleton has served as President and Chief Executive Officer and as a member of board of directors since November 2020. Previoly, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previoly at Teva Pharmaceutical Indtries, Ltd. (Teva) from November 1996 to December 2014, where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervo System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. Mr. Congleton's knowledge of biness and his extensive executive experience at multiple biopharmaceutical companies contributed to board of directors' conclion that he should serve as a director of company. - Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
- Jon Congleton has served as President and Chief Executive Officer and as a member of board of directors since November 2020. Previoly, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previoly at Teva Pharmaceutical Indtries, Ltd. (Teva) from November 1996 to December 2014, where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervo System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. Mr. Congleton's knowledge of biness and his extensive executive experience at multiple biopharmaceutical companies contributed to board of directors' conclion that he should serve as a director of company.
- Derek DiRocco
-
Derek DiRocco自2021年11月起在Acrivon Therapeutics，Inc.董事会任职。DiRocco博士自2020年12月起担任投资经理RA Capital Management，LLC的合伙人，此前曾于2017年12月至2020年12月担任首席分析师，于2015年6月至2017年12月担任分析师，并于2013年7月至2015年6月担任助理。DiRocco博士自2018年4月起担任89bio董事会成员，自2020年3月起担任iTeos Therapeutics董事会成员，自2020年8月起担任Connect Biopharma Holdings Limited董事会成员，自2020年12月起担任Werewolf Therapeutics公司董事会成员。他此前于2019年9月至2022年5月在Achilles Therapeutics plc董事会任职。DiRocco博士拥有圣十字学院生物学学士学位和华盛顿大学药理学博士学位，并在布莱根妇女医院/哈佛医学院进行博士后研究。
Derek DiRocco has served as a member of board of directors since October 2024. Dr. DiRocco has been a partner at RA Capital Management since December 2020. Dr. DiRocco works on both public and private investments and serves as a board director for 89Bio, Mineralys, Werewolf Therapeutics, Acrivon Therapeutics, Rivus Pharmaceuticals, Forward Therapeutics and Sera Medicines. Dr. DiRocco joined RA Capital Management in July 2013 and initially covered solid tumor oncology landscapes, later broadening coverage to multiple therapeutic areas. Dr. DiRocco holds a B.A. in Biology from Holy Cross College and a Ph.D. in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women's Hospital/Harvard Medical School, where he researched signaling pathways responsible for chronic and acute kidney disease, as well as cellular mechanisms underlying fibrotic disease. - Derek DiRocco自2021年11月起在Acrivon Therapeutics，Inc.董事会任职。DiRocco博士自2020年12月起担任投资经理RA Capital Management，LLC的合伙人，此前曾于2017年12月至2020年12月担任首席分析师，于2015年6月至2017年12月担任分析师，并于2013年7月至2015年6月担任助理。DiRocco博士自2018年4月起担任89bio董事会成员，自2020年3月起担任iTeos Therapeutics董事会成员，自2020年8月起担任Connect Biopharma Holdings Limited董事会成员，自2020年12月起担任Werewolf Therapeutics公司董事会成员。他此前于2019年9月至2022年5月在Achilles Therapeutics plc董事会任职。DiRocco博士拥有圣十字学院生物学学士学位和华盛顿大学药理学博士学位，并在布莱根妇女医院/哈佛医学院进行博士后研究。
- Derek DiRocco has served as a member of board of directors since October 2024. Dr. DiRocco has been a partner at RA Capital Management since December 2020. Dr. DiRocco works on both public and private investments and serves as a board director for 89Bio, Mineralys, Werewolf Therapeutics, Acrivon Therapeutics, Rivus Pharmaceuticals, Forward Therapeutics and Sera Medicines. Dr. DiRocco joined RA Capital Management in July 2013 and initially covered solid tumor oncology landscapes, later broadening coverage to multiple therapeutic areas. Dr. DiRocco holds a B.A. in Biology from Holy Cross College and a Ph.D. in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women's Hospital/Harvard Medical School, where he researched signaling pathways responsible for chronic and acute kidney disease, as well as cellular mechanisms underlying fibrotic disease.
- Brian Taylor Slingsby
-
Brian Taylor Slingsby，M.P.H.于2019年5月31日创立了Mineralys，自那时以来一直担任Mineralys Therapeutics，Inc.董事会成员，并担任执行主席。Slingsby博士是Catalys Pacific的Founder兼管理合伙人，Catalys Pacific是一家专注于生命科学的风险投资公司。除了在Mineralys创立和孵化期间担任创始首席执行官外，Slingsby博士还担任过Pathalys Pharma，Inc.，Kirilys Therapeutics，Inc.和Aculys Pharma，KK的创始首席执行官。在加入Catalys Pacific之前，他创立了全球卫生创新技术基金，这是世界上第一个专注于为中低收入国家开发新药的公私基金。斯林斯比博士以优异的成绩毕业于布朗大学，在京都大学和东京大学获得硕士学位和博士学位，并在乔治华盛顿大学获得博士学位。
Brian Taylor Slingsby,founded Mineralys on May 31, 2019 and has served on Mineralys Therapeutics, Inc. board of directors since that time and as Executive Chairman. Dr. Slingsby is Founder & Managing Partner at Catalys Pacific, a venture capital firm focused on life sciences. In addition to serving as founding CEO of Mineralys during its inception and incubation, Dr. Slingsby has served as founding CEO of Pathalys Pharma, Inc., Kirilys Therapeutics, Inc. and Aculys Pharma, KK. Previous to Catalys Pacific, he founded the Global Health Innovative Technology Fund, the world's first public-private fund focused on the development of new medicines for low- and middle-income countries. Dr. Slingsby graduated from Brown University with honors, earned his M.P.H. and Ph.D. from Kyoto University and the University of Tokyo, and received his M.D. with honors from the George Washington University. - Brian Taylor Slingsby，M.P.H.于2019年5月31日创立了Mineralys，自那时以来一直担任Mineralys Therapeutics，Inc.董事会成员，并担任执行主席。Slingsby博士是Catalys Pacific的Founder兼管理合伙人，Catalys Pacific是一家专注于生命科学的风险投资公司。除了在Mineralys创立和孵化期间担任创始首席执行官外，Slingsby博士还担任过Pathalys Pharma，Inc.，Kirilys Therapeutics，Inc.和Aculys Pharma，KK的创始首席执行官。在加入Catalys Pacific之前，他创立了全球卫生创新技术基金，这是世界上第一个专注于为中低收入国家开发新药的公私基金。斯林斯比博士以优异的成绩毕业于布朗大学，在京都大学和东京大学获得硕士学位和博士学位，并在乔治华盛顿大学获得博士学位。
- Brian Taylor Slingsby,founded Mineralys on May 31, 2019 and has served on Mineralys Therapeutics, Inc. board of directors since that time and as Executive Chairman. Dr. Slingsby is Founder & Managing Partner at Catalys Pacific, a venture capital firm focused on life sciences. In addition to serving as founding CEO of Mineralys during its inception and incubation, Dr. Slingsby has served as founding CEO of Pathalys Pharma, Inc., Kirilys Therapeutics, Inc. and Aculys Pharma, KK. Previous to Catalys Pacific, he founded the Global Health Innovative Technology Fund, the world's first public-private fund focused on the development of new medicines for low- and middle-income countries. Dr. Slingsby graduated from Brown University with honors, earned his M.P.H. and Ph.D. from Kyoto University and the University of Tokyo, and received his M.D. with honors from the George Washington University.
- Daphne Karydas
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Glenn Sblendorio
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Alexander M. Gold
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Srinivas Akkaraju
-
Srinivas Akkaraju，医学博士、哲学博士。他2003年7月起担任公司董事。2013年4月起，他是Sofinnova Ventures的普通合伙人。2009年1月至2013年4月，他是New Leaf Venture Partners的常务董事。2006年8月至2008年12月，他是私募股权公司Panorama Capital, LLC的常务董事，该公司由JPMorgan Chase & Co.旗下的私募股权部J.P. Morgan Partners, LLC的前风险投资团队创立。Panorama Capital曾建议J.P. Morgan Partners投资Seattle Genetics。共同创立Panorama Capital前，他2001年4月加入J.P. Morgan Partners，2005年1月成为其合伙人。1998年10月至2001年4月，他在Genentech, Inc.业务和公司发展部工作，该公司现在是生物科技公司Roche Group的成员，最近一职是高级经理。加入Genentech前，他是Stanford University的毕业生，获得免疫学的医学博士和哲学博士学位。他获得Rice University生物化学和计算机科学的学士学位。除Seattle Genetics外，他也是上市生物科技公司Intercept Pharmaceuticals, Inc.的董事。此前，他曾任Versartis, Inc.、Barrier Therapeutics, Inc.、Eyetech Pharmaceuticals, Inc.以及Synageva Biopharma Corp.的董事，这些公司在其任职期间都是上市生物科技公司。他还曾担任国外上市生物科技公司Amarin Corporation plc的董事。
Srinivas Akkaraju has served as a member of the Board since March 2024. Dr. Akkaraju is a founder and managing member of Samsara BioCapital, a venture capital firm, a position he has held since March 2017, and has been a co founder and director of Kalaris Therapeutics since Augt 2025. From April 2013 to February 2016, Dr. Akkaraju served as a general partner of Sofinnova Ventures, a venture capital firm. From January 2009 to April 2013, Dr. Akkaraju served as managing director of New Leaf Venture Partners, a venture capital firm. Dr. Akkaraju presently serves on the board of directors of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., Inventiva S.A., and numero private biopharmaceutical companies. During the past five years, he served as a director of Syros Pharmaceuticals, Inc., Chinook Therapeutics, Inc., Jiya Acquisition Corp., and Intercept Pharmaceuticals, Inc. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University. - Srinivas Akkaraju，医学博士、哲学博士。他2003年7月起担任公司董事。2013年4月起，他是Sofinnova Ventures的普通合伙人。2009年1月至2013年4月，他是New Leaf Venture Partners的常务董事。2006年8月至2008年12月，他是私募股权公司Panorama Capital, LLC的常务董事，该公司由JPMorgan Chase & Co.旗下的私募股权部J.P. Morgan Partners, LLC的前风险投资团队创立。Panorama Capital曾建议J.P. Morgan Partners投资Seattle Genetics。共同创立Panorama Capital前，他2001年4月加入J.P. Morgan Partners，2005年1月成为其合伙人。1998年10月至2001年4月，他在Genentech, Inc.业务和公司发展部工作，该公司现在是生物科技公司Roche Group的成员，最近一职是高级经理。加入Genentech前，他是Stanford University的毕业生，获得免疫学的医学博士和哲学博士学位。他获得Rice University生物化学和计算机科学的学士学位。除Seattle Genetics外，他也是上市生物科技公司Intercept Pharmaceuticals, Inc.的董事。此前，他曾任Versartis, Inc.、Barrier Therapeutics, Inc.、Eyetech Pharmaceuticals, Inc.以及Synageva Biopharma Corp.的董事，这些公司在其任职期间都是上市生物科技公司。他还曾担任国外上市生物科技公司Amarin Corporation plc的董事。
- Srinivas Akkaraju has served as a member of the Board since March 2024. Dr. Akkaraju is a founder and managing member of Samsara BioCapital, a venture capital firm, a position he has held since March 2017, and has been a co founder and director of Kalaris Therapeutics since Augt 2025. From April 2013 to February 2016, Dr. Akkaraju served as a general partner of Sofinnova Ventures, a venture capital firm. From January 2009 to April 2013, Dr. Akkaraju served as managing director of New Leaf Venture Partners, a venture capital firm. Dr. Akkaraju presently serves on the board of directors of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., Inventiva S.A., and numero private biopharmaceutical companies. During the past five years, he served as a director of Syros Pharmaceuticals, Inc., Chinook Therapeutics, Inc., Jiya Acquisition Corp., and Intercept Pharmaceuticals, Inc. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University.
高管简历
中英对照 | 中文 | 英文- Jon Congleton
Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
Jon Congleton has served as President and Chief Executive Officer and as a member of board of directors since November 2020. Previoly, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previoly at Teva Pharmaceutical Indtries, Ltd. (Teva) from November 1996 to December 2014, where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervo System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. Mr. Congleton's knowledge of biness and his extensive executive experience at multiple biopharmaceutical companies contributed to board of directors' conclion that he should serve as a director of company.- Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
- Jon Congleton has served as President and Chief Executive Officer and as a member of board of directors since November 2020. Previoly, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previoly at Teva Pharmaceutical Indtries, Ltd. (Teva) from November 1996 to December 2014, where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervo System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. Mr. Congleton's knowledge of biness and his extensive executive experience at multiple biopharmaceutical companies contributed to board of directors' conclion that he should serve as a director of company.
- David Rodman
David Rodman是我们研发的执行Vice President。David于2017年加入ProQR，此前曾在Novartis Institute for Biomedical Research NIBR，Vertex Pharmaceuticals，Miragen Therapeutics和Nivalis Therapeutics担任领导职务。在2005年转到工业之前，David拥有杰出的学术生涯，领导科罗拉多大学遗传肺部疾病中心，并指导科罗拉多州丹佛市国家犹太医学和研究中心的囊性纤维化护理，教学和研究工作。在工业领域的12年中，David一直负责推动创新，将尖端科学转化为罕见疾病的变革性新疗法，包括CF，肺纤维化，肺动脉高压以及严重的免疫性和炎症性疾病。在Vertex Pharmaceuticals，他指导早期和晚期CF临床开发计划，包括Kalydeco®；，Orkambi®；和VX-661。David于1976年获得Haverford College经济学学士学位，1980年获得University of Pennsylvania医学博士学位，并在University of Colorado完成内科、肺部和重症监护医学培训。他曾担任the National Institutes of Health的顾问，入选美国临床研究学会（the American Society for Clinical Research），是美国心脏协会（the American Heart Association）的院士。
David Rodman has served as Chief Medical Officer since January 2021. Previoly, Dr. Rodman served in vario roles at miRagen, Vertex Pharmaceuticals Inc., and Novartis Institutes for BioMedical Research. Dr. Rodman was elected to the American Society for Clinical Investigation and named an Established Investigator and Fellow of the American Heart Association. Dr. Rodman received his medical degree from the University of Pennsylvania and was subsequently Board Certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine at the University of Colorado.- David Rodman是我们研发的执行Vice President。David于2017年加入ProQR，此前曾在Novartis Institute for Biomedical Research NIBR，Vertex Pharmaceuticals，Miragen Therapeutics和Nivalis Therapeutics担任领导职务。在2005年转到工业之前，David拥有杰出的学术生涯，领导科罗拉多大学遗传肺部疾病中心，并指导科罗拉多州丹佛市国家犹太医学和研究中心的囊性纤维化护理，教学和研究工作。在工业领域的12年中，David一直负责推动创新，将尖端科学转化为罕见疾病的变革性新疗法，包括CF，肺纤维化，肺动脉高压以及严重的免疫性和炎症性疾病。在Vertex Pharmaceuticals，他指导早期和晚期CF临床开发计划，包括Kalydeco®；，Orkambi®；和VX-661。David于1976年获得Haverford College经济学学士学位，1980年获得University of Pennsylvania医学博士学位，并在University of Colorado完成内科、肺部和重症监护医学培训。他曾担任the National Institutes of Health的顾问，入选美国临床研究学会（the American Society for Clinical Research），是美国心脏协会（the American Heart Association）的院士。
- David Rodman has served as Chief Medical Officer since January 2021. Previoly, Dr. Rodman served in vario roles at miRagen, Vertex Pharmaceuticals Inc., and Novartis Institutes for BioMedical Research. Dr. Rodman was elected to the American Society for Clinical Investigation and named an Established Investigator and Fellow of the American Heart Association. Dr. Rodman received his medical degree from the University of Pennsylvania and was subsequently Board Certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine at the University of Colorado.
- Adam Levy
Adam Levy自2019年起担任Private Brickell&；8217；S首席商务官。在加入Private Brickell之前，Levy先生于2016年至2019年担任MiragenTherapeutics，Inc.首席商务官纳斯达克股票代码:MGEN，一家临床阶段的生物制药公司，致力于发现和开发专有的RNA靶向疗法，特别关注microRNA及其在医疗需求高度未满足的疾病中的作用。Levy从2000年到2016年在Merrill Lynch，Pierce，Fenner&Smith Incorporated，Jefferies Group和Wedbush Securities Inc.担任多个投资银行职位。Levy先生在康奈尔大学（Cornell University）获得应用经济学学士学位。
Adam Levy has served as Chief Financial Officer since March 2022 and as Chief Biness Officer from March 2022 through January 4, 2024. Mr. Levy also serves as a member of the board of directors of Praxis Bioresearch. Previoly, he was the Chief Financial Officer at Sanifit Therapeutics until the company was acquired by Vifor Pharma in 2022. Previoly, Adam served as the Chief Biness Officer at Brickell Biotech from 2019 to 2020 and led the organization's financial operations transition as it became a publicly listed company on Nasdaq. Prior to that, he served as the Chief Biness Officer at miRagen Therapeutics from 2016 to 2019, where he was responsible for a variety of functions including financial strategy, investor relations, biness development, legal affairs, intellectual property, project and program management, and human resources. Between 2000 and 2016, Mr. Levy held multiple investment banking positions at Merrill Lynch, Jefferies Group, and Wedbush Securities. Mr. Levy received a B.S. in Business Management and Marketing from Cornell University.- Adam Levy自2019年起担任Private Brickell&；8217；S首席商务官。在加入Private Brickell之前，Levy先生于2016年至2019年担任MiragenTherapeutics，Inc.首席商务官纳斯达克股票代码:MGEN，一家临床阶段的生物制药公司，致力于发现和开发专有的RNA靶向疗法，特别关注microRNA及其在医疗需求高度未满足的疾病中的作用。Levy从2000年到2016年在Merrill Lynch，Pierce，Fenner&Smith Incorporated，Jefferies Group和Wedbush Securities Inc.担任多个投资银行职位。Levy先生在康奈尔大学（Cornell University）获得应用经济学学士学位。
- Adam Levy has served as Chief Financial Officer since March 2022 and as Chief Biness Officer from March 2022 through January 4, 2024. Mr. Levy also serves as a member of the board of directors of Praxis Bioresearch. Previoly, he was the Chief Financial Officer at Sanifit Therapeutics until the company was acquired by Vifor Pharma in 2022. Previoly, Adam served as the Chief Biness Officer at Brickell Biotech from 2019 to 2020 and led the organization's financial operations transition as it became a publicly listed company on Nasdaq. Prior to that, he served as the Chief Biness Officer at miRagen Therapeutics from 2016 to 2019, where he was responsible for a variety of functions including financial strategy, investor relations, biness development, legal affairs, intellectual property, project and program management, and human resources. Between 2000 and 2016, Mr. Levy held multiple investment banking positions at Merrill Lynch, Jefferies Group, and Wedbush Securities. Mr. Levy received a B.S. in Business Management and Marketing from Cornell University.
- Eric Warren
Eric Warren自2025年4月起担任首席商务官。Previoly，Warren先生曾任职于商业阶段的生物制药公司Esperion Therapeutics, Inc.，最近一次任职是在2022年3月至2025年4月期间，担任该公司的首席商务官，并在2021年1月至2022年3月期间担任销售和营销副总裁。从2020年8月到2021年1月，Warren先生在商业阶段的生物制药公司Nabriva Therapeutics plc担任副总裁兼销售和营销主管。从2018年4月到2020年8月，Warren先生在其心血管专营权的制药和医疗保健公司赛诺菲 S.A.担任市场营销副总裁职务。此外，从2006年5月到2018年4月，Warren先生在制药公司默沙东公司担任越来越重要的职务。Warren先生拥有药学理学学士学位，是纽约州的一名执业药剂师。
Eric Warren has served as Chief Commercial Officer since April 2025. Previoly, Mr. Warren was at Esperion Therapeutics, Inc., a commercial stage biopharmaceutical company, where he most recently served as its Chief Commercial Officer from March 2022 to April 2025, and previoly in roles as Vice President, Sales and Marketing from January 2021 to March 2022. From Augt 2020 to January 2021, Mr. Warren was Vice President, Head of Sales and Marketing at Nabriva Therapeutics plc, a commercial stage biopharmaceutical company. From April 2018 to Augt 2020, Mr. Warren held Vice President roles in marketing at Sanofi S.A., a pharmaceutical and healthcare company, in their cardiovascular franchise. Additionally, from May 2006 to April 2018, Mr. Warren held roles of increasing responsibility at Merck & Co., a pharmaceutical company. Mr. Warren holds a Bachelor of Science in Pharmacy and is a licensed pharmacist in New York State.- Eric Warren自2025年4月起担任首席商务官。Previoly，Warren先生曾任职于商业阶段的生物制药公司Esperion Therapeutics, Inc.，最近一次任职是在2022年3月至2025年4月期间，担任该公司的首席商务官，并在2021年1月至2022年3月期间担任销售和营销副总裁。从2020年8月到2021年1月，Warren先生在商业阶段的生物制药公司Nabriva Therapeutics plc担任副总裁兼销售和营销主管。从2018年4月到2020年8月，Warren先生在其心血管专营权的制药和医疗保健公司赛诺菲 S.A.担任市场营销副总裁职务。此外，从2006年5月到2018年4月，Warren先生在制药公司默沙东公司担任越来越重要的职务。Warren先生拥有药学理学学士学位，是纽约州的一名执业药剂师。
- Eric Warren has served as Chief Commercial Officer since April 2025. Previoly, Mr. Warren was at Esperion Therapeutics, Inc., a commercial stage biopharmaceutical company, where he most recently served as its Chief Commercial Officer from March 2022 to April 2025, and previoly in roles as Vice President, Sales and Marketing from January 2021 to March 2022. From Augt 2020 to January 2021, Mr. Warren was Vice President, Head of Sales and Marketing at Nabriva Therapeutics plc, a commercial stage biopharmaceutical company. From April 2018 to Augt 2020, Mr. Warren held Vice President roles in marketing at Sanofi S.A., a pharmaceutical and healthcare company, in their cardiovascular franchise. Additionally, from May 2006 to April 2018, Mr. Warren held roles of increasing responsibility at Merck & Co., a pharmaceutical company. Mr. Warren holds a Bachelor of Science in Pharmacy and is a licensed pharmacist in New York State.